▣About ATAI Life Sciences N.V.

ATAI Life Sciences N.V. is a clinical‑stage biopharmaceutical company founded in 2018 to transform the treatment of mental health disorders; it was established by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde and is organized around a decentralized incubator model and a pipeline of psychedelic and non‑psychedelic programs.

In March 2025 the Nasdaq‑listed company announced a corporate treasury strategy that included an initial $5 million allocation to bitcoin to diversify cash reserves and mitigate inflation and valuation pressures.

The leadership team is led by co‑founder and CEO Srinivas Rao with co‑founder Christian Angermayer serving as Chairman; other senior executives include Anne Johnson (CFO), Kevin Craig (CMO), Glenn Short (CSO) and Gerd Kochendoerfer (COO).